The invention relates to the use of a compound of Formula (I) as described herein and its effective dose in the prevention and/or treatment of fibrosis diseases. The compound can effectively prevent and/or treat a fibrosis disease without cytotoxicity or genotoxicity.

This present disclosure relates to processes for removing contaminants from hydrocarbon streams, e.g. removing chlorides, CO.sub.2, COS, H.sub.2S, AsH.sub.3, methanol, mercaptans and other S- or O-containing organic compounds from olefins, paraffins, aromatics, naphthenes and other hydrocarbon streams. The process involves contacting the stream with an adsorbent which comprises a zeolite, an alumina component and a metal component e.g. sodium, in an amount at least 30% of the zeolite's ion exchange capacity.

This present disclosure relates to processes for removing contaminants from hydrocarbon streams, e.g. removing chlorides, CO.sub.2, COS, H.sub.2S, AsH.sub.3, methanol, mercaptans and other S- or O-containing organic compounds from olefins, paraffins, aromatics, naphthenes and other hydrocarbon streams. The process involves contacting the stream with an adsorbent which comprises a zeolite, an alumina component and a metal component e.g. sodium, in an amount at least 30% of the zeolite's ion exchange capacity.

The present disclosure relates generally to processes and systems for producing liquid transportation fuels by converting a feed stream that comprises both isopentane and n-pentane, and optionally, some C6+ hydrocarbons. Isopentane and smaller hydrocarbons are separated to form a first fraction while n-pentane and larger components of the feed stock form a second fraction. Each fraction is then catalytically-activated in a separate reaction zone with a separate catalyst, where the conditions maintained in each zone maximize the conversion of each fraction to olefins and aromatics, while minimizing the production of C1-C4 light paraffins. In certain embodiments, the first fraction is activated at a lower temperature than the second fraction. Certain embodiments additionally comprise mixing at least a portion of the two effluents and contacting with an oligomerization catalyst to provide enhanced yields of aliphatic hydrocarbons that possess the characteristics of a blend component of a liquid transportation fuel or other value-added chemical products.

The present disclosure relates generally to processes and systems for producing liquid transportation fuels by converting a feed stream that comprises both isopentane and n-pentane, and optionally, some C6+ hydrocarbons. Isopentane and smaller hydrocarbons are separated to form a first fraction while n-pentane and larger components of the feed stock form a second fraction. Each fraction is then catalytically-activated in a separate reaction zone with a separate catalyst, where the conditions maintained in each zone maximize the conversion of each fraction to olefins and aromatics, while minimizing the production of C1-C4 light paraffins. In certain embodiments, the first fraction is activated at a lower temperature than the second fraction. Certain embodiments additionally comprise mixing at least a portion of the two effluents and contacting with an oligomerization catalyst to provide enhanced yields of aliphatic hydrocarbons that possess the characteristics of a blend component of a liquid transportation fuel or other value-added chemical products.

The present disclosure relates to methods for treating an ANCA associated vasculitis, for example, granulomatosis with polyangiitis (GPA), with compositions comprising an effective amount of certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds of Formula (I), including pharmaceutically acceptable salts thereof,

##STR00001##

that inhibit dipeptidyl peptidase 1 (DPP1) activity. In one embodiment, the compound of Formula (I) is (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (INS1007).

The disclosures herein provide compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These salts may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, suppository, transdermal, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of irritable bowel syndrome (IBS), inflammatory bowel diseases or its associated complications.

The present disclosure provides a process for reducing oxygenate content of hydrocarbon feed. The process comprises passing and heating the hydrocarbon feed over ion exchange resin resident in a reactor, maintained at a temperature in the range of 90 to 140 C. and a predetermined pressure, at a predetermined liquid hourly space velocity to obtain a heated intermediate fluid. The heated intermediate fluid is cooled to obtain a cooled intermediate fluid. The cooled intermediate fluid is mixed with water to obtain a mixture. The mixture is allowed to settle to obtain an aqueous phase and an organic phase. The aqueous phase is separated from the organic phase to obtain hydrocarbon feed with reduced oxygenate content. The process is simple and environment friendly, enabling removal of 70-90% of the oxygenate content from the hydrocarbon feed.

The present disclosure provides a process for reducing oxygenate content of hydrocarbon feed. The process comprises passing and heating the hydrocarbon feed over ion exchange resin resident in a reactor, maintained at a temperature in the range of 90 to 140 C. and a predetermined pressure, at a predetermined liquid hourly space velocity to obtain a heated intermediate fluid. The heated intermediate fluid is cooled to obtain a cooled intermediate fluid. The cooled intermediate fluid is mixed with water to obtain a mixture. The mixture is allowed to settle to obtain an aqueous phase and an organic phase. The aqueous phase is separated from the organic phase to obtain hydrocarbon feed with reduced oxygenate content. The process is simple and environment friendly, enabling removal of 70-90% of the oxygenate content from the hydrocarbon feed.

Provided here are processes and systems for conversion of alkyl-bridged non-condensed alkyl multi-aromatic compounds to alkyl mono-aromatic compounds. One system includes a hydrodearylation reactor adapted to receive a hydrogen stream and a feed stream and to produce a reactor effluent stream in presence of a catalyst. The feed stream contains one or more of heavy alkyl aromatic compounds and one or more alkyl-bridged non-condensed alkyl multi-aromatic compounds. The reactor effluent stream contains one or more alkyl mono-aromatic compounds. The system also includes a first separator fluidly coupled to the hydrodearylation reactor and adapted to receive the reactor effluent stream and to produce a hydrodearylated gas stream and a hydrodearylated liquid stream. The system also includes a second separator fluidly coupled to the first separator and adapted to receive a portion of the hydrodearylated gas stream and to produce a hydrocarbon liquid stream and a vapor stream rich in hydrogen.